Disease activity at baseline and follow-up among patients clinically improving (n=68) or not (n=23)
| Improving by PRI (n=68) | Baseline Mean (SD) | Follow-up Mean (SD) | p Value (baseline to follow-up)* |
|---|---|---|---|
| PGA | 1.7 (0.4) | 0.8 (0.5) | <0.001 |
| SLEDAI | 10.4 (4.4) | 3.6 (3.7) | <0.001 |
| Global BILAG | 15.7 (6.9) | 4.8 (5.4) | <0.001 |
| Number of BILAG domains (A, B, C) | 2.8 (0.9) | 1.8 (1.0) | <0.001 |
| Number of BILAG domains (A, B) | 1.7 (0.8) | 0.4 (0.7) | <0.001 |
| Not improving by PRI (n=23) | |||
| PGA | 1.7 (0.3) | 1.7 (0.5) | 0.541 |
| SLEDAI | 9.0 (2.7) | 8.7 (4.3) | 0.747 |
| Global BILAG | 13.3 (4.8) | 12.5 (8.1) | 0.615 |
| BILAG domains (A, B, C) | 2.3 (0.6) | 2.2 (1.1) | 0.732 |
| BILAG domains (A, B) | 1.5 (0.7) | 1.4 (0.9) | 0.680 |
*Paired t test.
BILAG, British Isles Lupus Assessment Group; PGA, physician's global assessment; PRI, physician-rated improvement; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index.